CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo tested for advanced cancers: hope for lymphoma and solid tumors
Disease control TerminatedThis early-phase study tested a new experimental drug, PF-08046032, alone or combined with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 09:42 UTC
-
New lymphoma drug trial halted early after only 9 patients
Disease control TerminatedThis early-stage trial tested a new drug called GEN3017 in people with CD30-positive Hodgkin or non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The main goal was to check safety and find the right dose. Only 9 people took part before the study wa…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
Promising hodgkin lymphoma drug trial halted early – only 3 patients enrolled
Disease control TerminatedThis study tested a drug called tislelizumab against standard chemotherapy for people with classical Hodgkin lymphoma that returned or didn't respond to prior treatments. The trial aimed to see if tislelizumab could delay cancer progression. However, the study was stopped early a…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated May 22, 2026 14:04 UTC